. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Depress Anxiety. 2015 May 6;32(8):614–623. doi: 10.1002/da.22377

Table 3.

Number of treatment responders (and % ITT sample size) using conventional indices of clinical significance

	Post-Acute Treatment # Responders (% ITT)	3-Month Follow-up # Responders (% ITF)	9-Month Follow-up # Responders (% ITF)
GAD Clinical Response
ADIS GAD CSR < 4	17/21 (81.0%)	17/20 (85.0%)	18/20 (90.0%)
CGI-Improvement < 3	20/21 (95.2%)	19/20 (95.0%)	19/20 (95.0%)
30% Improvement (4+ of 6 Criteria Met)	17/21 (81.0%)	18/20 (90.0%)	18/20 (90.0%)
High Endstate Functioning (4+ of 6 Criteria Met)	14/21 (66.7%)	15/20 (75.0%)	17/20 (85.0%)
MDD Clinical Response
ADIS MDD CSR < 4	9/11 (82.0%)	10/10 (100%)	10/10 (100%)
30% Improvement (3+ of 4 Criteria Met)	6/11 (54.5%)	9/10 (90.0%)	6/10 (60.0%)
High Endstate Functioning (3+ of 4 Criteria Met)	5/11 (45.5%)	7/10 (70.0%)	8/10 (80.0%)

Note. All findings based upon ITT analyses at post-acute (N = 21) and ITF in the no-treatment follow-up periods (N = 20)